Literature DB >> 25027498

New pancreatic adenocarcinoma in a Crohn's patient treated with tumor necrosis factor (TNF) inhibitors for 6 months.

Rupal Patel1, Shanil Lara, Jean Johnson, Prasad Kulkarni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25027498     DOI： 10.1007/s12029-014-9640-9

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  9 in total

Review 1.  Hepatosplenic T-cell lymphoma and inflammatory bowel disease.

Authors:  Anne Thai; Thomas Prindiville
Journal:  J Crohns Colitis       Date:  2010-06-25       Impact factor: 9.071

Review 2.  Infectious and malignant complications of TNF inhibitor therapy in IBD.

Authors:  Laura E Targownik; Charles N Bernstein
Journal:  Am J Gastroenterol       Date:  2013-09-17       Impact factor: 10.864

Review 3.  Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature.

Authors:  David Hudesman; Simon Lichtiger; Bruce Sands
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

4.  Cancer after kidney transplantation in the United States.

Authors:  Bertram L Kasiske; Jon J Snyder; David T Gilbertson; Changchun Wang
Journal:  Am J Transplant       Date:  2004-06       Impact factor: 8.086

5.  Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-09

6.  Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.

Authors:  H Fidder; F Schnitzler; M Ferrante; M Noman; K Katsanos; S Segaert; L Henckaerts; G Van Assche; S Vermeire; P Rutgeerts
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

7.  Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands.

Authors:  Hilbert S de Vries; Martijn G H van Oijen; Dirk J de Jong
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 8.  Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer.

Authors:  George Kouklakis; Eleni I Efremidou; Michael Pitiakoudis; Nikolaos Liratzopoulos; Alexandros Ch Polychronidis
Journal:  Drug Des Devel Ther       Date:  2013-03-27       Impact factor: 4.162

Review 9.  Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

Authors:  Gerd R Burmester; Remo Panaccione; Kenneth B Gordon; Melissa J McIlraith; Ana P M Lacerda
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.